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Epstein—Barr	virus	 (EBV),	a	human	gammaher-
pesvirus	is	intimately	associated	with	nasopharyngeal	
carcinoma	 (NPC),	with	 the	 incidence	of	 the	 virus	
detected	 in	malignant	 tissues	being	close	 to	100%	
in	NPC	endemic	areas.	The	viral	 latent	protein,	 la-
tent	membrane	protein	1	(LMP1),	has	all	 the	typical	
characteristics	of	an	oncogene	and	extensive	studies	
have	shown	beyond	doubt	its	abilities	in	cellular	trans-
formation	giving	rise	to	malignant	phenotypes.	NPC	
carcinogenesis,	as	typical	as	any	other	solid	tumours,	
is	a	multi-step	process.	EBV	infection	that	culminates	
in	malignant	undifferentiated	NPC	is	known	to	occur	
early	 in	pre-malignant	or	pre-invasive	 lesions,	pre-
sumably	preceded	by	aberrant	genetic	events	such	
as	 loss	of	heterozygosity	 (LOH)	[1].	The	expression	
of	EBV	latent	genes	in	NPC	is	subjected	to	the	conse-
quences	of	host	immune	response	in	which	cytotoxic	
T-lymphocytes	(CTL)	plays	an	important	role	[2].	It	is	
thus	postulated	that	there	exist	dynamic	viral-specific	
immune-responses	at	different	tumour	stages	and	EBV	
adapts	accordingly	to	the	tumour	microenvironment.	
One	of	the	most	important	EBV	latent	genes	expressed	
in	NPC	is	the	viral	LMP1.	Its	expression	is	known	to	oc-
cur	early	in	the	pre-invasive	stage.	The	expression	of	
LMP1	in	NPC	has	an	interesting	feature.	It	was	shown	
by	 immunohistochemistry	 (IHC)	 that	LMP1	was	ex-
pressed	in	most	cells	during	the	pre-invasive	stage	but	
its	expression	was	detected	in	only	a	fraction	of	cells	
in	the	malignant	stage	[3].	These	observations	invoke	
the	question	of	whether	 the	difference	 in	 the	LMP1	
expression	pattern	in	the	pre-invasive	and	malignant	
lesions	 is	 the	 result	of	genotypic	selection	 imposed	
on	LMP1	in	the	course	of	tumourigenesis.	Under	the	
influence	of	such	host	selective	pressure,	this	present	
study	hypothesizes	that	there	exist	a	selection	process	
in	the	progress	from	the	pre-malignant	to	the	malignant	
stages	of	NPC	that	culminates	in	the	selection	for	the	
LMP1	 genotype	 that	 is	expressed	 in	 the	malignant	
stage.	 In	other	words,	we	hypothesized	 that	LMP1	
genes	derived	from	patients	with	different	stages	of	
NPC	differ	 in	 their	sequences	and	consequently,	 in	
their	biological	properties.
Material and Methods
Cell lines. TW01	is	an	EBV-negative	epithelial	NPC	
cell	 line	established	from	biopsy	specimens	of	NPC	
patients	in	Taiwan,	kindly	provided	by	Prof	S.W.	Tsao	
of	the	Hong	Kong	University,	China	SAR	[4].	TW01	was	
used	as	 the	host	cell	 for	 the	expression	of	different	
LMP1	gene	variants.	As	it	was	our	interest	to	assess	
the	biological	properties	conferred	by	different	LMP1	
genes	derived	from	two	patients	with	different	histo-
logical	stages	of	NPC,	 it	 thus	 justified	the	use	of	an	
EBV-negative	NPC	cell	line	instead	of	a	normal	epithe-
lial	line.	B95.8	and	AG876	were	cultured	in	RPMI-1640,	
while	TW01,	in	DMEM/F-12.	Both	media	were	supple-
mented	with	10%	v/v	foetal	calf	serum	(FCS).	All	cells	
were	maintained	in	an	incubator	at	37	°C,	5%	CO2	and	
sub-cultured	in	1	:	10	dilutions	 in	the	same	medium	
unless	for	specific	applications.
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Clinical samples. The	collection	of	 all	 clinical	
samples	was	subjected	to	prior	approval	by	the	Ethics	
Committee	of	the	University	of	Malaya	Medical	Centre	
(UMMC)	and	after	 informed	consent	has	been	ob-
tained	from	each	individual.	Fresh	PNS	biopsies	were	
collected	from	the	ENT	Clinic,	UMMC,	under	the	su-
pervision	of	Prof.	U.	Prasad.	Two	biopsy	samples	were	
collected	from	patients	suspected	of	NPC	—	one	for	
RNA	extraction	and	other	for	histological	examination.	
Subsequently,	two	biopsy	tissues	from	two	unrelated	
patients	were	used	 for	 further	 laboratory	 investiga-
tions.	These	consisted	of	one	pre-malignant	 tissue	
with	high-grade	dysplasia	and	one	malignant,	stage	
II	NPC	 tissue	 (UICC/AJCC	classification	1997),	 as	
confirmed	by	a	qualified	pathologist.	The	specimens	
meant	 for	RNA	extraction	were	 immediately	kept	 in	
RNAlater®	(Qiagen,	USA)	and	stored	in	–80	°C	to	pre-
serve	the	RNA.
LMP1 cDNA cloning. Reverse	transcription	(RT)	
followed	by	Polymerase	Chain	reaction	(PCR)	was	per-
formed	using	the	Superscript	III	One-step	RT-PCT	
System	(Invitrogen,	USA)	following	the	manufacturer’s	
recommendations.	 LMP1	 gene-specific	 primers	
(M-AR:	GCC	ACC ATG	GAA	CAC	GAC	CTT	GAG	AGG	
GGC,	EBV	co-ordinates:	169207–169230;	and	CF:	
TTA GTC	ATA	GTA	GCT	TAG	CTG	AAC	TGG,	EBV	co-
ordinates:	168163–168186)	at	0.2	μM	concentrations	
were	used	in	a	total	reaction	volume	of	50	μL	contain-
ing	the	following	components;	0.2	mM	of	each	dNTP,	
1.2	mM	MgSO4,	RT/Platinum	Taq	polymerase	mixture	
and	1	μg	of	RNA.	Primers	M-AR	and	CF	contained	the	
Kozak’s	fragment	and	termination	codon	respectively	
as	underlined	in	bold).	The	RT	was	performed	at	50	°C	
for	30	min	and	terminated	by	incubating	at	94	°C	for	
two	min.	Immediately,	the	completed	RT	reaction	was	
subjected	to	40	cycles	of	PCR	amplifications	consist-
ing	of	the	following	steps;	94	°C,	15	s;	55	°C,	30	s	and	
72	°C,	two	min.	Amplified	product	were	analysed	by	
agarose	gel	 electrophoresis	 and	 fragments	of	 the	
correct	size	were	cloned	into	the	pcDNA3.1	TOPO-TA	
vector	(Invitrogen,	USA)	following	the	supplier’s	pro-
tocol.	As	an	LMP1-negative	control	 vector,	 the	hu-
man	β-globin	gene	was	amplified	and	ligated	to	the	
pcDNA3.1	TOPO-TA	vector	in	order	to	produce	a	co-
valent-closed	circular	plasmid	and	the	β-globin	gene	
was	subsequently	deleted	by	BstX1	digestion	and	the	
empty	plasmid	re-ligated.	This	LMP1-negative	control	
vector	was	used	to	transfect	the	TW01	cells	to	establish	
to	the	LMP1-negative	clone.	
DNA sequencing. DNA	sequencing	of	the	cloned	
LMP1	cDNA	in	pcDNA3.1	vector	was	performed	us-
ing	a	set	of	three	primers;	S1	(5’-TAA	TAC	GAC	TCAC	
TAT	AGG	G-3’),	S3	(5’-TCA	CCC	TCC	TGC	TCA	TCG	
C-3’)	and	S5	(5’-ACG	GAC	CCC	CAC	TCT	GCT	CTC	
AAA-3’).	The	S1	primer	corresponded	to	the	T7	pro-
moter	 sequence	 located	upstream	of	 the	plasmid	
multiple	cloning	site.	The	S3	primer	corresponded	
to	the	first	19	residues	of	exon	b	of	the	LMP1	mRNA	
(EBV	coordinate:	169110–169128),	while	primer	S5	
corresponded	to	the	internal	sequence	of	exon	c	of	
LMP1	mRNA	 (EBV	Coordinate:	 168600–168623).	
Sequencing	was	performed	by	Research	Biolabs	Sdn.	
Bhd.,	Kuala	Lumpur,	at	their	facility	using	the	ABI	Prism	
373	DNA	Sequencer.	The	sequenced	DNA	results	for	
each	LMP1	clone	was	aligned	and	compared	with	the	
B95.8	LMP1	sequence	(Gene	Bank	Acc.	No.:	V01555)	
using	 the	Megalign®	program	of	 the	Lasergene®	v.5	
suite	(DNASTAR	Inc.,	USA).
Establishment of LMP1-expressing TW01 
clones. LMP1-expressing	TW01	cell	clones	were	es-
tablished	by	transfecting	the	cells	with	pcDNA-LMP1	
plasmids	that	carried	LMP1	genes	derived	from	the	
pre-malignant	(NORLMP1)	and	malignant	(NPCLMP1)	
tissues	as	well	as	the	wild-type	gene	from	B95.8	cells.	
The	fluorescence	protein	expression	plasmid,	pECFP,	
was	used	 to	optimize	 the	 transfection	efficiencies.	
Transfection	of	the	epithelial	cells	was	performed	us-
ing	Lipofectamine	2000	(Invitrogen,	USA)	according	
to	the	supplier’s	recommendation.	Transfected	cells	
were	incubated	for	48	h	at	37	°C	with	5%	CO2	and	trans-
gene	expressing	cells	were	selected	by	passaging	at	
1	:	10	dilutions	in	fresh	selection	medium,	DMEM-10	
supplemented	with	 200	μg/mL	Geneticin	 (G418).	
Stable	clones	were	obtained	by	routine	passaging	in	
the	selection	medium	for	up	to	four	weeks.
In vitro invasion assay. The	 invasive	ability	of	
LMP1-expressing	TW01	cells	was	assessed	using	the	
BD	Biocoat	Tumour	Invasion	System	(BD	Bioscien-
ces,	USA)	following	the	supplier’s	recommendations.	
Sub-confluent	cells	were	harvested	by	 trypsinization	
and	suspended	 in	DMEM/F-12	at	a	cell	 density	of	
1.0	×	105/mL	 for	2	h	at	RT.	The	suspended	cells,	 in	
0.5	mL	aliquots,	were	added	to	each	well	containing	the	
Matrigel®-coated	insert	and	were	incubated	for	48	h	at	
37	°C,	with	5%	CO2.	Non-coated	membrane	inserts	as	
well	as	TW01	transfected	with	the	empty	vector	were	
also	seeded	 to	serve	as	controls.	Following	 incuba-
tion,	the	upper	membrane	surfaces	of	the	inserts	were	
gently	scrubbed	with	a	cotton	swab	to	remove	all	the	
non-invading	cells.	The	invading	cells	that	had	traversed	
across	 the	membrane	 to	 the	bottom	of	 the	well	was	
counted	using	an	improved	Neubauer	hemocytometer	
after	staining	with	1%	w/v	Evans	blue	solution.
Apoptosis assays. LMP1-transfected	and	empty	
vector-transfected	TW01	cells	were	assessed	for	their	
resistance	 to	apoptosis	 induced	by	staurosposine.	
Cells	were	grown	 to	80%	confluence	 in	 a	 96-well	
culture	plate	and	 the	growth	medium	was	 replaced	
by	DMEM/F-12,	10%	v/v	FCS	and	supplemented	with	
either	500	nM	staurosporine	or	62.5	ng/mL	of	FasL	
(Sigma,	USA).	Two	types	of	assays	were	performed	
to	detect	apoptosis	in	cells	—	cytochrome	c	release	
and	caspase-3	activation.	Cytochrome	c	release	as-
say	was	used	to	assess	the	integrity	of	the	apoptotic	
mechanisms	in	TW01	cells	and	was	performed	using	
the	 reagents	supplied	 in	 the	cytochrome	c	Release	
Apoptosis	Assay	Kit® (Oncogene	Research	Products,	
USA)	following	the	supplier’s	recommendations.	To-
tal	cellular	protein	contents	in	both	the	cytosolic	and	
mitochondrial	 fractions	were	determined	using	 the	
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method	by	Bradford	and	10	μg	protein	was	analysed	
in	10%	SDS-PAGE.	Cytochrome	c	was	detected	using	
the	mouse	monoclonal	anti-cytochrome	c	IgG	supllied	
by	the	kit.	Caspase-3	activity	in	staurosporine-induced	
cells	was	determined	using	the	Caspase-3	Assay	Kit	
(Sigma,	USA)	following	the	supplier’s	recommenda-
tions.	Briefly,	staurosporine-induced	cells	grown	in	a	
96-well	culture	plate	were	washed	once	 in	PBS	and	
incubated	on	ice	for	20	min	in	25	μL	lysis	buffer	sup-
plied	with	the	kit.	Following	incubation,	200	μL	of	assay	
buffer	containing	Ac-DEVD-AMC	was	added	to	each	
well.	The	plate	was	 incubated	at	37	 °C	 to	allow	suf-
ficient	time	for	substrate	digestion.	The	fluorescence	
intensity	in	each	well	resulting	from	the	release	of	the	
AMC	moiety	was	determined	using	an	image	analyzer	
with	the	scanning	parameters	set	to	excite	at	360	nm	
and	detect	at	460	nm.
Regulation of E-cadherin (CDH1) expression. 
The	mRNA	 transcript	 levels	of	CDH1	 in	 transfected	
TW01	cells	were	quantified	using	reverse-transcription	
coupled	 to	 real-time	quantitative	PCR	using	 iCycler	
iQ	Real	Time	PCR	system	(Bio-Rad,	USA).	In	develo-
ping	the	real-time	quantitative	assay,	the	E-cadherin	
gene	plasmid	construct	was	first	generated	by	clon-
ing	 the	 full	 length	E-cadherin	 (Gene	Bank	Acc.	No.	
AB025106)	amplified	from	LMP1-negative	TW01	cells.	
The	2.8	kb	reverse	transcribed	amplimer	was	cloned	
into	 pcDNA-TOPO-TA	 vector.	 This	CDH1	plasmid	
construct,	pcDNA-Ecad,	was	used	as	standards	in	the	
quantitative	assay.	The	standards	consisted	of	serially	
diluted	pcDNA-Ecad	plasmids	ranging	from	1.0	×	102	
to	1.0	×	107	copies	 in	10-fold	 increments.	A	 five	μL	
aliquot	containing	250	ng	of	RNA	extracted	from	cells	
were	subjected	to	reverse-transcription	(RT)	followed	
by	conventional	amplification.	The	combined	RT-PCR	
was	done	using	the	TaqMan®	One-Step	RT-PCR	Mas-
ter	Mix	Reagents	(Applied	Biosystems,	USA).	CDH1	
mRNA	was	quantified	using	the	primers,	E-cadRTF	(5’-	
CCG	CGT	CCT	GGG	CAG	AGT	GAA	T-3’)	and	E-cadRTR	
(5’-	TCC	CAG	GCG	TAG	ACC	AAG	AAA	TG-3’),	and	
detected	with	the	TaqMan®	probe	(5’-	FAM-CGA	TTC	
AAA	GTG	GGC	ACA	GAT	GGT-TAMRA).	GAPDH	was	
used	as	an	internal	control	to	normalize	the	E-cadherin	
transcript	levels	between	different	samples.	One-step	
RT-PCR	was	performed	in	a	50	μL	reaction	volume	that	
contained	 the	 following	components;	1.25	U	Multi-
Scribe	reverse	transcriptase	(supplied	with	the	kit),	
300	nM	of	each	primer,	25	nM	of	TaqMan	probe,	4	mM	
MgCl2,	200	µM	of	each	dATP,	dCTP	and	dGTP;	400	µM	
of	dUTP;	0.5	U	AmpErase	uracil	N-glycosylase	(UNG)	
and	1.25	U	AmpliTaq	Gold.	Amplification	parameters	
consisted	of	 the	 following	step	 in	sequential	order;	
cDNA	synthesis	at	42	°C	for	30	min,	UNG	activation	at	
50	°C	for	2	min,	initial	denaturation	at	95	°C	for	8	min,	
followed	by	40	cycles	of	95	°C	for	30	s	and	56	°C	for	
1	min.	Amplification	 for	each	sample	and	standard	
was	performed	 in	duplicates.	A	standard	curve	was	
only	accepted	if	the	correlation	coefficient	is	0.996	or	
higher	and	its	slope	ranged	between	–3.74	to	–3.32,	
which	correlates	to	amplification	efficiency	of	between	
85	to	100%	respectively.	The	fluorescence	detection	
threshold	value	was	set	at	10	×	 the	mean	standard	
deviation	of	fluorescence	in	all	reactions.
Statistical analysis. All	statistical	analyses	were	
performed	using	the	program	SPSS	(Statistical	Pro-
gram	 for	Social	Sciences;	SPSS	 Inc,	USA).	Means	
of	paired	samples	were	analysed	using	 the	Paired	
Sample t-test.	Means	of	independent	samples	were	
analysed	using	Independent	Sample	t-test.	Samples	
from	two	or	more	groups	with	a	factor	having	two	or	
more	 levels	were	analysed	using	One-way	Analysis	
of	Variance	(ANOVA).	The	ANOVA	F	test	was	used	to	
evaluate	whether	the	group	means	on	the	dependent	
variable	differ	significantly	from	each	other.
results 
NORLMP1 and NPCLMP1 differed in their 
amino acid sequences.	DNA	sequencing	of	the	pre-
malignant	tissue-derived	NORLMP1	and	the	malignant	
tissue-derived	NPCLMP1,	 revealed	numerous	base	
substitutions,	in	addition	to	deletions,	along	the	LMP1	
gene.	The	corresponding	amino	acid	sequences	are	
presented	in	Fig.	1.	NORLMP1	had	a	total	of	20	mu-
tations	detected	with	respect	to	the	wild-type	B95.8	
LMP1.	Of	 these,	18	were	single	base	substitutions	
with	13	of	them	being	non-conservative	and	resulted	
in	 amino	acid	 substitutions.	Some	of	 these	muta-
tions	were	also	reported	 in	CAOLMP1	(from	China),	
2117-LMP1	(from	Hong	Kong)	and	1510-LMP1	from	
Taiwan	[5,	6,	7].	The	remaining	two	mutations	were	the	
30-bp	and	15-bp	deletions	that	resulted	in	deletions	
of	their	corresponding	10	and	5	amino	acid	residues,	
respectively.	The	30-bp	deletion	which	resulted	in	the	
deletion	of	10	amino	acids	(H345_G354del)	was	also	
evident	 in	CAOLMP1,	2117-LMP1	and	1510-LMP1.	
By	comparison,	NPCLMP1	harboured	a	significantly	
higher	number	of	mutations.	A	total	of	45	mutations	
were	detected	in	NPCLMP1	to	be	at	variant	with	the	
B95.8	LMP1.	Of	these,	42	were	single	base	substitu-
tions	with	24	of	them	being	non-conservative.	Similar	
to	NORLMP1,	 the	30-bp	deletion	was	detected	 in	
NPCLMP1	but	not	the	15-bp	deletion.	Some	of	the	24	
non-conservative	mutations	were	also	reported	in	the	
Asian	isolates	as	mentioned	[5,	6].	The	presence	of	
the	30-bp	deletion	(168266_168295del)	and	the	loss	
of	Xho1	restriction	site	(169425C	>	A)	 in	NORLMP1	
and	NPCLMP1	were	also	 shown	 independently	by	
PCR	(results	not	shown).	The	prevalence	of	the	30-bp	
deletion	in	NORLMP1,	NPCLMP1	and	other	NPC-as-
sociated	LMP1	variants	derived	 from	China,	Hong	
Kong	and	Taiwan	underscored	the	intimate	association	
of	this	deletion	with	NPC.	Of	note,	the	15-bp	deletion	
(168479_168493del)	detected	 in	NORLMP1	but	not	
in	NPCLMP1	was	also	detected	 in	CAOLMP1	and	
1510-LMP1	but	not	in	2117-LMP1.	In silico	analyses	of	
sequence	data	using	Lasergene	v.5.0	(DNASTAR	Inc.,	
USA)	for	NORLMP1	and	NPCLMP1	indicated	a	protein	
length	of	371	and	382	amino	acids	respectively.	With	
a	few	exceptions,	most	of	the	amino	acid	changes	in	
both	NORLMP1	and	NPCLMP1	did	not	occur	in	the	im-
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portant	functional	motifs	along	the	different	functional	
domains	of	LMP1.	 In	NORLMP1,	 the	only	mutation	
that	directly	affected	a	functional	motif	was	the	dele-
tion	(P275_L279del)	in	one	of	the	two	CTAR3	motifs,	
275PXXPXT208.	This	deletion	also	 resulted	 in	 the	 loss	
of	one	internal	11-bp	repeat	unit.	On	the	other	hand,	
amino	acid	changes	were	detected	in	the	N-terminal	
(R13P	and	R17L)	and	trans-membrane	(I173L)	domains	
of	NPCLMP1.	In	addition	to	these,	an	insertion	of	six	
amino	acid	residues	(P278_L279insDNTDDN)	and	a	
single	residue	substitution	(L279G)	were	detected	in	
motif	box	1	of	the	CTAR3	domain.	The	insertion	of	six	
amino	acid	residues	added	one	unit	of	internal	repeat	
thus	giving	a	total	of	 five	complete	11-bp	repeats	 in	
NPCLMP1	compared	to	the	typical	four	repeats	pres-
ent	in	both	NORLMP1	and	the	B95.8	LMP1.	NORLMP1	
and	NPCLMP1	shared	six	non-conservative	mutations;	
I85L,	F106Y,	I122L,	M129I,	S309N	and	L388S,	in	addi-
tion	to	the	deletion	of	10	amino	acids	(H345_G354del).	
All	these	mutations	with	the	exception	of	S309N	were	
also	detected	 in	CAOLMP1,	2117-LMP1	and	1510-
LMP1	 [5,6,7].	Although	not	detected	 in	CAOLMP1,	
S309N	has	been	reported	in	2117-LMP1,	1510-LMP1	
and	LMP1	of	other	EBV	strains	such	as	China-1,	China-
2	and	Mediterranean	 [8,	9].	Of	note,	 four	and	 two	
mutually	exclusive	non-conservative	mutations	were	
detected	 in	NORLMP1	and	NPCLMP1,	 respectively	
that	were	not	present	 in	CAOLMP1,	2117-LMP1	and	
1510-LMP1.	The	four	mutations	specific	to	NORLMP1	
were	M61I,	S229T,	D298A	and	D372N.	The	two	spe-
cific	mutations	detected	 in	NPCLMP1	were	G115A	
and	H276Q.	M61I,	S229T	and	D298A	were	reported	
in	AG876	EBV	[10].	S229T	was	also	detected	 in	 the	
LMP1	of	C15	strain	[11].	G115A	was	reported	in	the	RV	
EBV	stain	isolated	from	an	NPC	biopsy	[6].
NORLMP1 and NPCLMP1-transfected TW01 
cells demonstrated different biological proper-
ties.	Success	of	transfection	and	expression	of	LMP1	
in	TW01	clones	was	examined	by	RT-PCR	targeting	the	
LMP1	gene	(Fig.	2)	and	immunofluorescence	micros-
copy	using	the	CS1-4	monoclonal	antibody	specific	to	
LMP1	(Fig.	3).	Both	methods	confirmed	the	expres-
sion	of	LMP1s	in	TW01	cells.	These	LMP1-expressing	
TW01	clones	—	TW01-B95LMP1,	TW01-NORLMP1	
and	TW01-NPCLMP1;	and	the	LMP1-negative	TW01	
control	were	used	in	subsequent	experiments.	
In vitro invasion assay.	 LMP1-expressing	NPC	
cells	were	reported	to	be	more	progressive	and	showed	
a	greater	tendency	of	lymph	node	metastasis	than	the	
LMP1-negative	counterpart	[12].	The	invasiveness	of	
the	TW01	cells	that	expressed	NORLMP1,	NPCLMP1	
and	B95LMP1	recombinant	proteins	were	compared	
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fig. 1. Amino	acid	sequence	of	NPCLMP1	and	NORLMP1.	Graphical	representation	on	the	comparison	of	amino	acid	sequences	of	
NPCLMP1,	NORLMP1	and	B95.8	LMP1	proteins.	The	B95.8	LMP1	sequence	was	obtained	from	Swiss-Prot	Protein	Database	(Acc.	
No.:	P03230).	Amino	acid	residues	are	represented	in	the	single	letter	code	and	numbered	with	reference	to	B95.8	LMP1.	Residues	
in	NORLMP1	and	NPCLMP1	that	differ	from	B95.8	LMP1	are	highlighted	in	grey.	The	domains	of	LMP1	are	indicated	in	the	B95.8	
sequence.	N-terminal	(aa	1–24)	is	highlighted	in	blue,	trans-membrane	(25–186)	is	highlighted	in	yellow.	The	C-terminal	activating	
regions	are	boxed	and	labeled	while	the	respective	motifs	are	highlighted	in	green;	CTAR1	(aa	194–232),	CTAR3	(aa	275–330)	and	
CTAR2	(351–386).	Asterisks	indicate	the	internal	repeats
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using	an	in vitro	invasion	assay.	Highest	invasive	capa-
bility	was	demonstrated	by	TW01-NORLMP1	with	the	
highest	number	of	 invasive	cells	(3.0	×	104	 invading	
cells/mL)	followed	by	TW01-NPCLMP1	(5.0	×	103	in-
vading	cells/mL)	and	TW01-B95LMP1	(2,500)	(Table).	
None	of	 the	LMP1-negative	control	cells	were	able	
to	invade	across	the	matrix	into	the	lower-side	of	the	
wells.	These	results	demonstrate	that	not	all	EBV	LMP1	
genes	conferred	the	same	invasive	potential	and	TW01	
that	expressed	the	LMP1	derived	from	the	dysplastic	
tissue	was	more	invasive	than	its	counterpart	that	ex-
pressed	the	malignant	tissue	derived	LMP1.	
fig. 2. Reverse-transcript	PCR	of	LMP1.	RT-PCR	of	the	LMP1	
gene	derived	from	the	newly	established	LMP1-expressing	TW01	
clones.	RT-PCR	was	performed	on	RNA	derived	from	each	cell	
line	using	LMP1-specific	primers	—	M-AR	and	CF.	Lanes	1:	
Molecular	Markers,	2:	B95.8	control,	3:	LMP1-negative	TW01,	4:	
TW01-B95LMP1,	5;	TW01-NORLMP1	and	6:	TW01-NPCLMP1
Table. In vitro invasion assay.  Each cell line was seeded in duplicates and 
the number of invasive cells in each well was determined after 48 h
Cell Line Number of invasive cell / mLReplicate 1 Replicate 2 Mean
TWO1 0 0 0
TWO1-B95LMP1 2500 2500 2500
TWO-NPCLMP1 5000 5000 5000
TWO1-NORLMP1 36250 23750 30000
Apoptosis assay. EBV	LMP1	is	known	to	protect	
B	cells	from	apoptosis	by	up-regulating	anti-apoptosis	
factors	such	as	A20	and	Bcl-2	[13,	14].	However,	the	
knowledge	of	the	roles	of	LMP1	in	protecting	epithelial	
NPC	cells	from	apoptosis	is	currently	incomplete.	At	
present,	one	study	has	established	the	susceptibility	
of	NPC	to	FasL-induced	apoptosis	through	the	cas-
pase-dependent	pathway	 [15].	 In	 the	 time-course	
staurosporine	 induction	study,	cytochrome	c	could	
be	detected	 in	both	 the	mitochondrial	 and	cytosol	
fractions	at	every	 time	 interval	 tested	 (Fig.	4).	This	
observation	 indicates	 the	preservation	of	an	 intact	
apoptotic	pathway	and	sensitivity	of	TW01	cells	 to	
staurosporine-induced	cell	death.
Next,	 the	sensitivity	of	 the	NORLMP1,	NPCLMP1	
and	B95LMP1-expressing	TW01	cells	 to	staurospo-
rine-induced	apoptosis	was	 investigated.	 Induction	of	
apoptosis	was	assayed	based	on	the	activation	of	the	
protease,	caspase-3.	Fluorescence	 intensity,	corre-
sponding	to	the	caspase	activity	was	determined	one	
hour	after	the	addition	of	substrate	and	was	expressed	
as	percentage	increase	over	the	blank	reactions	devoid	
of	the	apoptotic	stimulants	(%∆460nm	Fluorescent	Unit	or	
%∆460nm	FU).	Thus,	higher	%∆460nm	FU	value,	 indicated	
fig. 3. Immunofluorescence	staining	of	LMP1-expressing	TW01	
cells.	Immunofluorescence	staining	of	the	LMP1	protein	in	TW01-
B95LMP1,	TW01-NORLMP1	and	TW01-NPCLMP1.	CS1-4	(Dako)	at	
a	1	:	200	dilution	was	used	as	the	primary	antibody	followed	by	Alexa-
Fluor	594	conjugated-chicken	anti-mouse	IgG	(Molecular	Probes)	
at	a	1	:	200	dilution	as	the	secondary	for	fluorescence	detection.	(a)	
LMP1-negative	TW01,	(b)	TW01-B95LMP1,	(c)	TW01-NORLMP1,	(d)	
TW01-NPCLMP1.	All	images	were	taken	at	100	×	magnification
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higher	caspase	activity	and	hence	greater	the	extent	of	
apoptosis	and	vice	versa.	Strong	indication	of	cell	death	
was	observed	in	the	LMP1-negative	TW01	cells	following	
stimulation	by	staurosporine	(57%∆460nm	FU).	This	was	
followed	by	TW01-NORLMP1	(21%∆460nm	FU),	TW01-
B95LMP1	(6%∆460nm	FU)	and	TW01-NPCLMP1	(4%∆460nm	
FU)	(Fig.	5).	These	differences	in	mean	percentage	in-
crease	in	fluorescence	unit	among	the	different	cell	lines	
were	significant	except	between	TW01-B95LMP1	and	
TW01-NPCLMP1	(One-way	ANOVA,	p	≥	0.05)	(Fig.	5).	
fig. 4. Time-course	induction	of	cytochrome	c	using	anti-cy-
tochrome	c	monoclonas	release	in	LMP1-negative	TW01	cells.	
Cytochrome	c	was	detected.	The	cytochrome	c	proteins	were	
detected	as	bands	corresponding	to	circa	20	and	40	kDa.	Cells	
were	 treated	with	DMEM/F-10	medium	supplemented	with	
500	nM	staurosporine,	an	apoptosis	inducer.	The	detection	of	
cytochrome	c	in	the	mitochondrial	fractions	(Lanes	2	to	5)	and	in	
its	cytosolic	fractions	(Lanes	6	to	9)	indicated	the	positive	induc-
tion	of	cell	death	by	apoptosis.	Lanes	2	and	6:	3	h;	Lanes	3	and	
7:	6	h;	Lanes	4	and	8:	9	h;	Lanes	5	and	9:	18	h	
fig. 5. Fluorogenic	assay	of	staurosporine-induced	caspase-3	
activity	in	TW01	clones.	Fluorogenic	assay	of	staurosporine-induced	
caspase-3	activity	in	TW01	clones.	Caspase	activity	measured	as	
the	mean	percentage	change	in	fluorescence	unit	(%∆460nm	FU)	
indicative	of	cells	undergoing	apoptosis	are	presented	as	solid	
bars	with	standard	deviations.	There	were	no	differences	in	mean	
caspase	activities	between	TW01-B95LMP1	and	TW01-NPCLMP1	
in	response	to	staurosporine	(One-way	ANOVA,	p	≥	0.05)
Regulation of E-cadherin (CDH1) expression. 
LMP1	has	 lately	been	documented	to	down-regulate	
the	expression	of	E-cadherin,	the	effect	of	which	leads	
to	enhancement	in	metastatic	potential	[16].	However,	
no	studies	have	so	far	investigated	the	regulatory	effect	
of	this	gene	by	LMP1	derived	from	different	histologi-
cal	stages	of	NPC.	The	E-cadherin	protein,	encoded	
by	 the	CDH1	gene,	 is	a	classical	cadherin	 from	 the	
cadherin	superfamily	and	loss	of	function	is	thought	to	
contribute	to	progression	in	cancer	by	increasing	pro-
liferation,	invasion,	and/or	metastasis	[17].	The	CDH1	
transcript	was	detected	in	all	LMP1-expressing	TW01	
clones	as	well	as	in	the	LMP1-negative	control.	In	order	
to	compare	 the	 levels	of	CDH1	 in	different	samples,	
the	transcript	level	of	this	gene	was	normalized	against	
the	level	of	a	ubiquitous	house-keeping	gene,	GAPDH.	
CDH1	was	detected	at	3.67	×	104	copies/μg	RNA	 in	
the	LMP1-negative	TW01	control.	However,	 signifi-
cantly	lower	levels	of	CDH1	transcripts	were	observed	
in	LMP1-expressing	cells	(Fig.	6).	Of	the	TW01	clones	
tested,	 the	 levels	of	CDH1	 in	NORLMP1-expressing	
cells	(956	copies/μg	RNA)	was	~	2.5	times	lower	than	
in	 the	clone	expressing	NPCLMP1	(2360	copies/μg	
RNA).	Reduction	in	the	level	of	CDH1	transcripts	were	
also	detected	in	TW01	clone	expressing	the	wild-type	
B95LMP1	gene	(1916	copies/μg	RNA).
fig. 6. LMP1	downregulates	E-cadherin	(CDH1).	LMP1	down-
regulates	E-cadherin	as	determined	using	real-time	quantitative	
PCR.	TW01	cells	 transfected	with	NORLMP1	 and	NPCLMP1	
recorded	a	 significant	 reduction	 in	CDH1	expression.	Each	
bar	represents	the	mean	value	and	standard	errors	for	assays	
conducted	in	duplicates	and	normalized	to	the	levels	of	GAPDH	
transcript
discussion 
This	study	compares	the	sequence	and	biological	
properties	of	EBV	LMP1	derived	 from	 two	NPC	pa-
tients	—	one	presented	with	a	pre-invasive	lesion	with	
high	grade	dysplasia	and	the	other	presented	with	ma-
lignant	NPC	stage	II	(UICC/AJCC	classification	1997).	
It	was	hypothesized	that	there	exist	specific	variants	of	
LMP1	genes	expressed	at	different	histological	stages	
in	the	progress	from	pre-malignant	to	malignant	NPC.	
This	hypothesis	was	based	on	 the	 findings	of	Path-
manathan	et	al.	[3],	whereby	the	authors	showed	that	
EBV	infection	of	the	Fossa	of	Rosenmüller	(FOR),	the	
site	known	for	its	predilection	to	malignant	NPC,	was	
an	early	event	with	the	viral	gene	products	including	
EBERs	and	LMP1,	being	detected	as	early	as	in	pre-
invasive,	dysplastic	lesions.	The	procurement	of	the	
pre-invasive	lesion	from	which	the	NORLMP1	gene	was	
isolated	was	an	arduous	task	as	patients	were	often	
presented	at	the	ENT	clinic	with	clinical	symptoms	only	
after	malignancy	had	developed.	This	problem	was	
confounded	by	the	fact	that	the	progression	from	the	
pre-invasive	to	the	malignant	NPC	is	a	rapid	one.	The	
patients	from	whom	the	NORLMP1	gene	was	isolated	
succumbed	to	stage	II	NPC	within	one	year.	
Sequence	analyses	made	on	the	cDNAs	derived	
from	 the	pre-malignant	 (NORLMP1)	and	malignant	
tissue-derived	LMP1	(NPCLMP1)	identified	DNA	se-
172	 Experimental	Oncology	29,	166–174,	2007	(September)
quences	that	were	at	variant	with	each	other.	Both	the	
15-bp	and	the	30-bp	deletions	reported	in	CAOLMP1	
[5]	were	found	in	NORLMP1.	NPCLMP1	has	only	the	
30-bp	deletion	but	base	insertion	in	the	internal	repeat	
regions	of	 the	gene	resulted	 in	an	additional	unit	of	
repeat.	These	deletions	and	insertions	translated	into	
NORLMP1	and	NPCLMP1	proteins	that	were	respec-
tively,	371	and	382	amino	acid	(aa)	residues	in	length	
as	compared	to	386	aa	in	the	wild-type.	Both	LMP1	
variants	also	possessed	numerous	base	substitutions	
along	 the	gene	with	 respect	 to	 the	wild-type	B95.8	
LMP1	 [18].	 The	 six	 non-conservative	point	muta-
tions	shared	by	NORLMP1	and	NPCLMP1	were	also	
reported	 in	NPC-derived	LMP1	variants	 from	China	
(China	1	and	2),	including	Hong	Kong	(2117-LMP1),	
and	Taiwan	(1510-LMP1).	Of	particular	interest	was	the	
presence	of	M129I	mutation	 in	both	NORLMP1	and	
NPCLMP1.	This	mutation	has	been	reported	recently	
to	be	associated	with	increased	half-life	of	the	LMP1	
protein	[19].	The	sequence	data	(see	Fig.	1)	show	that	
the	NORLMP1	and	NPCLMP1	proteins,	 resembled	
their	counterpart	derived	 from	 the	nude	mice	pas-
saged	NPC,	CAOLMP1	[5]	based	on	the	number	of	
identical	mutation,	notably	 the	30-bp	deletions	and	
base	substitutions.	
The	establishment	of	stable	TW01	clones	express-
ing	NORLMP1,	NPCLMP1	and	the	prototypical	LMP1	
from	B95.8	EBV,	B95LMP1	(as	LMP1	positive	control),	
represented	 the	 first	 step	 in	which	 the	 functions	of	
these	LMP1	variants	were	subsequently	 tested	and	
compared	against	 the	background	of	EBV-negative	
TW01	NPC	cells.	The	use	of	TW01	 line	allowed	 the	
biological	 assessment	 of	 EBV	 LMP1	 that	was	not	
confounded	by	the	presence	of	other	EBV	genes	and	
hence	the	functional	implication	of	LMP1	in	NPC	could	
be	exclusively	implicated.	
The	NORLMP1-expressing	TW01	clone	was	shown	
to	confer	the	greatest	overall	invasive	capability	(see	
Table).	As	none	of	 the	LMP1-negative	cells	 invaded	
the	Matrigel®-coated	membrane,	 it	was	clear	 that	
this	 invasive	property	was	conferred	by	LMP1.	This	
is	in	agreement	with	a	report	using	a	closely	related	
EBV-negative	NPC	epithelial	cell	line,	TW03.	By	infect-
ing	 the	otherwise	EBV-negative	TW03	cells	 through	
co-cultivation	with	EBV-positive	Akata	cells,	 Tera-
moto	et al.	[20]	were	able	to	demonstrate	the	greatly	
enhanced	in vitro	invasive	ability	of	the	EBV-infected	
cell	over	its	parental	counterpart.	Their	observations	
postulated	 that	EBV	 infection	 restored	 the	 invasive	
capability	of	EBV-negative	NPC	cells	and	this	present	
study	 indicated	 that	 this	capability	was	specifically	
conferred	by	LMP1.
There	was	a	correlation	between	invasive	capability	
and	the	cellular	levels	of	E-cadherin	(CDH1)	in	LMP1-
expressing	cells.	In	comparison	to	the	LMP1-negative	
cells,	 the	expression	of	NORLMP1	and	NPCLMP1	
significantly	suppressed	the	transcript	level	of	CDH1 
by	several	orders	of	magnitude	(see	Fig.	6).	Moreover,	
the	extent	of	suppression	induced	by	NORLMP1	was	
2.5-fold	greater	than	that	induced	by	NPCLMP1.	This	
observation	was	consistent	with	the	sequence	data	of	
the	two	LMP1	variants	(see	Fig.	1)	which	show	that	the	
integrity	of	the	CTAR2	domain	motif	critical	for	CDH1	
repression	through	the	NF-κB	signaling	pathway	[21]	
was	maintained	and	unaffected	by	mutations.	How-
ever,	the	two	mutations	specific	to	NORLMP1,	S366T	
and	D372N,	 though	 they	did	not	 reside	within	 the	
CTAR2	motif,	might	be	responsible	for	its	enhanced	
ability	 over	NPCLMP1	 in	 suppressing	E-cadherin	
expression.	The	ability	 to	down-regulate	CDH1	may	
thus	explain	 the	 invasive	nature	of	NORLMP1	and	
NPCLMP1-expressing	TW01	clones	and	showed	that	
the	suppression	of	CDH1	may	be	one	of	the	several	
ways	by	which	LMP1	induces	metastasis	in	an	other-
wise	non-invasive	TW01	NPC	cell.	This	confirms	an	
earlier	 study	which	 reported	an	enhanced	 invasive	
capability	across	 type-1	collagen	gel	as	a	 result	of	
decreased	cellular	expression	of	CDH1	in	LMP1-ex-
pressing	RHEK-1	cells	[22].
The	apoptotic	mechanism	in	TW01	cells	was	shown	
to	be	intact	as	they	were	sensitive	to	staurosporine-
induce	cytochrome	c	release	(see	Fig.	4).	Cytochrome	
c	 release	 from	 the	mitochondria	 to	 the	cytosol	 is	a	
well-known	early	event	 leading	to	 the	caspase	acti-
vation	cascades	and	ultimately	apoptosis.	Assay	for	
caspase-3	indicated	that	NPCLMP1	conferred	signifi-
cantly	higher	anti-apoptotic	potential	than	NORLMP1	
in	TW01	cells	(see	Fig.	5).	This	observation	could	be	
corroborated	with	clinical	data	whereby	early	but	not	
advanced	stage	NPC	is	known	to	be	sensitive	to	both	
radio	 and	 chemotherapies	 [23].	 Interestingly,	 the	
2117-LMP1	that	bears	amino	acid	sequence	homology	
to	NPCLMP1 was	also	shown	to	enhance	 the	resis-
tance	of	epithelial	cells	against	apoptosis	induced	by	
growth	factor	deprivation	[24].	
This	present	study	is	the	first	in	pursuing	the	notion	
that	LMP1	derived	from	lesions	of	different	histological	
stages	are	also	at	variant	in	their	biological	properties.	
The	discovery	of	sequence	and	functional	variations	
between	the	LMP1	derived	from	the	pre-malignant	le-
sion	(NORLMP1)	and	the	malignant	lesion	(NPCLMP1)	
implied	that	there	existed	a	dynamic	selection	pressure	
on	 the	viral	oncogene	during	 the	progress	of	NPC.	
This	observation	was	consistent	with	the	report	on	the	
dynamic	shifts	in	cytotoxic	T-cell	epitopes	that	select	
for	a	particular	LMP1	variant	during	the	development	of	
NPC	and	render	the	viral	oncogene	non-immunogenic	
[25,	26].	Both	30-bp	deletion	and	Xho1	polymorphism	
detected	in	both	NORLMP1	and	NPCLMP1	indicated	
an	early	selection	event	for	these	mutations	in	NPC.	
However,	the	presence	of	these	mutations	alone	could	
not	account	 for	 their	manifested	differences	 in	bio-
logical	functions.	Hence	the	important	contributions	of	
non-conservative	point	mutations	that	have	not	been	
fully	addressed	to	date.	
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биологические свойства клеток tw01, 
экспрессирующих ген латентного мембранного 
белка 1 вэб, выделенного из клеток рака носоглотки 
различной степени злокачественности
Обоснование и цель: вирус Эпштейна—Барр (ВЭБ), герпесвирус человека, ассоциирован с развитием рака носоглотки 
(РНГ): вирус выявляют в малигнизированной ткани практически в 100% случаев. Ген, ко�ирую�ий латентный мем�ранный     
�елок 1 (LMP1�, о�ла�ает типичными характеристиками онкогена; в ря�е иссле�ований про�емонстрирована его спосо�-
ность вызывать трансформацию клеток и развитие злокачественного фенотипа. В �анной ра�оте прове�ено сравнение 
нуклеоти�ной после�овательности генов LMP1, вы�еленных из ткани РНГ �вух �ольных (с �исплазией/пре�раком и 
РНГ ІІ ста�ии соответственно) и �иологических свойств клеток, трансфецированных �тими генами.  Методы: сравнивали 
нуклеоти�ные после�овательности генов LMP1 из о�разцов пре�раковой (NORLMP1� и опухолевой (NPCLMP1� тканей и 
соответственно аминокислотные после�овательности ко�ируемых ими �елков. Гены NORLMP1 и NPCLMP1 встраивали в 
клетки ВЭБ-отрицательной линии TW01 и иссле�овали �иологические свойства трансфецированных клеток, в частности         
их спосо�ность к инвазивному росту in vitro , устойчивость к апоптозу и �кспрессии Е-ка�герина (CDH1). Результаты: 
о�а �елка — NORLMP1 и NPCLMP1 — значительно отличались по аминокислотной после�овательности от �елка LMP1            
�икого типа (B95,8), и клетки линии TW01, в которых они �кспрессировались, различались по �иологическим свойствам.             
Клетки TW01, �кспрессирую�ие NORLMP1, о�ла�али �олее злокачественным фенотипом, чем таковые, �кспрессирую�ие          
NPCLMP1, по показателям инвазивной спосо�ности, устойчивости к апоптозу и регуляции �кспрессии CDH1.            Выводы: 
полученные �анные сви�етельствуют о том, что гены LMP1, вы�еленные из о�разцов �иопсии �вух �ольных с различными 
ста�иями РНГ, отличаются по нуклеоти�ной после�овательности, что проявляется в различиях �иологических свойств 
клеток, трансфецированных соотвествую�ими генами. 
Ключевые слова: вирус Эпштейна—Барр, ген LMP1, рак носоглотки, �иологические свойства, злокачественность.
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